接受glecaprevir/pibrentasvir治疗丙型肝炎病毒感染失败患者的再治疗。 - Suppr

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.

作者信息

Wyles David, Weiland Ola, Yao Betty, Weilert Frank, Dufour Jean-Francois, Gordon Stuart C, Stoehr Albrecht, Brown Ashley, Mauss Stefan, Zhang Zhenzhen, Pilot-Matias Tami, Rodrigues Lino, Mensa Federico J, Poordad Fred

机构信息

Denver Health Medical Center, Denver, CO, USA.

Karolinska University Hospital Huddinge, Stockholm, Sweden.

出版信息

J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.

DOI:10.1016/j.jhep.2019.01.031

PMID:30857780

Abstract

摘要

相似文献

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.

J Hepatol. 2019 May;70(5):1019-1023. doi: 10.1016/j.jhep.2019.01.031. Epub 2019 Mar 8.

Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.

J Hepatol. 2017 Aug;67(2):263-271. doi: 10.1016/j.jhep.2017.03.039. Epub 2017 Apr 13.

Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy.

Clin J Gastroenterol. 2020 Apr;13(2):267-270. doi: 10.1007/s12328-019-01039-w. Epub 2019 Aug 28.

Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.

Lancet Infect Dis. 2017 Oct;17(10):1062-1068. doi: 10.1016/S1473-3099(17)30496-6. Epub 2017 Aug 14.

Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).

Lancet Gastroenterol Hepatol. 2020 Sep;5(9):839-849. doi: 10.1016/S2468-1253(20)30086-8. Epub 2020 Jul 16.

Successful ongoing retreatment with glecaprevir/pibrentasvir + sofosbuvir + ribavirin in a patient with HCV genotype 3 who failed glecaprevir/pibrentasvir with both NS3 and NS5A resistance.

Clin Microbiol Infect. 2020 Sep;26(9):1266-1268. doi: 10.1016/j.cmi.2020.03.022. Epub 2020 Mar 30.

Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.

Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15.

Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.

Clin Gastroenterol Hepatol. 2019 Feb;17(3):527-535.e6. doi: 10.1016/j.cgh.2018.07.003. Epub 2018 Sep 10.

Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.

J Gen Virol. 2019 Jul;100(7):1123-1131. doi: 10.1099/jgv.0.001268. Epub 2019 Jun 14.

Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration.

J Infect Dis. 2020 Sep 1;222(7):1165-1169. doi: 10.1093/infdis/jiaa219.

引用本文的文献

Genotyping and treatment issues with 'unusual' HCV 1 subtypes.

Eur J Clin Microbiol Infect Dis. 2025 May;44(5):1265-1271. doi: 10.1007/s10096-025-05038-3. Epub 2025 Feb 26.

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks.

J Virol. 2025 Feb 25;99(2):e0184324. doi: 10.1128/jvi.01843-24. Epub 2025 Jan 22.

Unlocking hope: HCV re-treatment strategy for patients with active hepatocellular carcinoma.

JHEP Rep. 2024 Apr 7;6(11):101093. doi: 10.1016/j.jhepr.2024.101093. eCollection 2024 Nov.

Prevalence of Drug Resistance Associated Substitutions in Persons With Chronic Hepatitis C Infection and Virological Failure Following Initial or Re-treatment With Pan-genotypic Direct-Acting Antivirals: A Systematic Review and Meta-analysis.

Clin Infect Dis. 2024 Dec 17;79(6):1437-1446. doi: 10.1093/cid/ciae431.

[Glecaprevir/pibrentasvir in combination with ribavirin as salvage therapy in chronic hepatitis C].

Rev Esp Quimioter. 2024 Jun;37(3):283-284. doi: 10.37201/req/020.2024. Epub 2024 Apr 19.

SASLT guidelines: Update in treatment of hepatitis C virus infection, 2024.

Saudi J Gastroenterol. 2024 Jan 1;30(Supp 1):S1-S42. doi: 10.4103/sjg.sjg_333_23. Epub 2024 Jan 3.

Glecaprevir-pibrentasvir for 4 weeks among people with recent HCV infection: The TARGET3D study.

JHEP Rep. 2023 Jul 27;5(10):100867. doi: 10.1016/j.jhepr.2023.100867. eCollection 2023 Oct.

Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Trial Design Considerations.

Clin Infect Dis. 2023 Aug 14;77(Suppl 3):S262-S269. doi: 10.1093/cid/ciad362.

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.

World J Gastroenterol. 2023 Feb 14;29(6):949-966. doi: 10.3748/wjg.v29.i6.949.

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.

World J Gastroenterol. 2022 Dec 7;28(45):6380-6396. doi: 10.3748/wjg.v28.i45.6380.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献